Sage — Metabolic Hypothesis of Autoimmune Gastritis
Autoimmune gastritis is not primarily a story of rogue T cells that have decided, for reasons of genetic bad luck or molecular mimicry, to attack parietal-cell H+/K+-ATPase. It is more usefully understood as a downstream expression of chronic mitochondrial energetic shortfall—local in the oxyntic mucosa and systemic—whose consequences include redox stress, altered iron handling, impaired immune tolerance, and progressive loss of the very cells whose work is among the most ATP-intensive in the human body. Low ferritin is not merely a laboratory inconvenience to be corrected with iron tablets; it is a sentinel of that bioenergetic and redox strain. The immune attack is real and destructive, yet it is secondary: a compensatory or dysregulated response once the metabolic orchestrator has already failed.
This is the same framing that appears across the metabolic hypotheses of atherosclerosis, cancer origin, aging, and eukaryote–gut biota symbiosis. Metabolism is the higher-order regulator. Immunity, iron homeostasis, and tissue architecture are effectors that respond to the state of cellular energy production, redox balance, and substrate availability. When we treat only the effectors—suppress the clones, replace the missing iron and B12, monitor for neuroendocrine tumors—we are adjusting the dashboard while the engine continues to lose power.
Parietal Cells, Acid, and the Energetic Cost of Proton Pumping
Parietal cells maintain a million-fold proton gradient. The H+/K+-ATPase is one of the most demanding ion pumps in mammalian physiology. Its continuous operation requires robust oxidative phosphorylation, intact mitochondrial membrane potential, and efficient handling of the reactive oxygen species that inevitably accompany high electron-transport-chain flux. Any sustained impairment in mitochondrial ATP generation or redox control will preferentially stress these cells. Apoptosis, impaired biogenesis, or simple energetic failure then exposes intracellular antigens, including the proton pump itself, to an immune system already primed by low-grade inflammation or impoverished microbial education.
A genetic clue exists. Certain ATP4A mutations produce achlorhydria together with mitochondrial biogenesis defects, elevated ROS, and caspase-mediated parietal-cell death; the autoimmune response follows rather than initiates the damage. The mutation is rare, yet it illustrates the principle: when the energetic and redox machinery of the parietal cell is compromised, autoimmunity becomes a predictable sequel. In the far more common sporadic form of AIG the initiating insult need not be genetic. It can be chronic substrate or cofactor shortage, excess oxidative load, circadian disruption, or the systemic mitochondrial strain that accompanies modern metabolic disease. Once a critical mass of parietal cells is lost, achlorhydria ensues, iron absorption collapses (ferric iron requires acid for solubilization), intrinsic-factor production falls, and the familiar cascade of low ferritin, eventual B12 deficiency, and hypergastrinemia appears.
Ferritin as Bioenergetic Sentinel
Ferritin is conventionally read as a storage protein. In the setting of AIG it is more informative to treat it as a real-time reporter of cellular redox and energetic stress. Low circulating ferritin can reflect true depletion secondary to malabsorption, but it can also reflect sequestration driven by inflammatory and redox signals (hepcidin upregulation, Nrf2-mediated responses). In either case the signal is upstream of simple iron deficiency. Chronic mitochondrial ROS generation and mtDNA/mtRNA release activate innate sensors (cGAS-STING, inflammasomes). The resulting cytokine milieu alters iron trafficking. Simultaneously, the loss of gastric acid prevents replenishment of stores. The dashboard shows low ferritin; the engine is under power and under oxidative load.
This is why years of oral iron supplementation often fail to normalize ferritin in AIG while the underlying process continues. Replacing the missing element without restoring the conditions that allow its proper handling and utilization is classic downstream medicine.
Mitochondrial–Immune Crosstalk and Loss of Tolerance
Immunometabolism has established that T-cell and macrophage fate is not determined solely by antigen recognition. Metabolic state—glycolysis versus oxidative phosphorylation, availability of TCA intermediates, fatty-acid oxidation capacity, and mitochondrial ROS tone—biases differentiation toward effector or regulatory phenotypes. When OXPHOS is impaired, the balance frequently tilts toward Th17-like inflammatory states and away from Treg-mediated tolerance. Excess mitochondrial damage-associated molecular patterns further activate innate pathways that lower the threshold for loss of self-tolerance.
In AIG the target antigen is restricted, yet the same principles apply. Pre-existing mitochondrial strain in the gastric mucosa or systemically can lower the threshold at which autoreactive clones escape control. Once the attack is underway, the inflammatory microenvironment further damages remaining mitochondria, closing a vicious loop. Genetic predisposition (HLA associations) and possible molecular mimicry with H. pylori remain relevant; they simply operate on a metabolic substrate that either permits or resists progression to overt disease.
The gut biota is not a bystander. We are holobionts. The primary ongoing symbiont educates immune tolerance, supplies short-chain fatty acids that support colonocyte and systemic mitochondrial function, and helps set the inflammatory tone of the entire organism. When that partnership frays—through loss of diversity, absence of keystone fermenters, or chronic dietary insult—the default state tilts toward inflammation and failed discrimination between self and non-self. Autoimmune gastritis is one of many possible downstream expressions of that upstream ecological and metabolic compromise.
Limitations of a Raw-Vegetable or Strictly Plant-Based Pattern
A diet built predominantly on raw or minimally processed vegetables is frequently advanced as anti-inflammatory and antioxidant-rich. In the specific context of AIG and of the broader holobiont framework it carries important limitations.
First, bioavailability. Heme iron, preformed B12, and certain amino-acid profiles critical for mitochondrial biogenesis and membrane repair are either absent or poorly absorbed from plant sources. In a patient already suffering achlorhydria and intrinsic-factor deficiency, reliance on non-heme iron and plant precursors becomes even less tenable. Collagen peptides or isolated supplements can paper over some gaps; they do not restore the evolutionary package of animal-sourced nutrients that human parietal cells and immune cells evolved to expect.
Second, the raw state itself. Many plant secondary compounds (oxalates, lectins, phytates, goitrogens) are reduced by cooking or fermentation. In a gut already compromised by low acid and altered microbiota, high intakes of unprocessed plant material can increase antigenic load and further disrupt the symbiotic dialogue rather than restore it. Fermented microbiota-accessible carbohydrates (sauerkraut, kimchi, properly prepared legumes and tubers) are a different matter: they deliver both the fiber substrate and the live or residual microbial metabolites that support butyrate production and immune education. Raw volume without fermentation does not reliably achieve the same end.
Third, the energetic and membrane requirements of the eukaryotic host. Mitochondrial membranes and the plasma membranes of highly active cells such as parietal cells require specific fatty-acid compositions and cholesterol. Strict exclusion of animal fats removes a ready source of these lipids and of the fat-soluble vitamins that travel with them. The holobiont solution that evolution selected was never a pure plant pattern; it was a partnership between eukaryotic host metabolism (supported by animal and fermented foods) and a diverse microbial consortium fed by complex plant polysaccharides that had been rendered more bioavailable by traditional preparation methods.
None of this argues for the absence of plants. It argues against the ideological elevation of a raw or exclusively plant-based pattern as universally optimal, especially when the clinical picture already includes malabsorption and mitochondrial strain. Context, absorption capacity, and the full nutrient matrix matter more than dietary purity.
Orchestrator Versus Effector
Precision immune interventions that identify and temper specific autoreactive clones can limit ongoing tissue destruction and thereby create space for recovery. They are not inherently "chasing downstream" if the clonal expansion is actively driving the inflammatory loop. Yet if the higher-order metabolic state continues to favor effector over regulatory phenotypes and to generate mitochondrial damage signals, the same clones or new ones are likely to re-emerge. The more durable strategy pairs targeted control of the immune effector with aggressive restoration of the metabolic orchestrator: mitochondrial biogenesis and quality control, redox balance, substrate availability matched to absorptive capacity, circadian alignment, and re-establishment of a metabolically competent gut biota through fermented foods and appropriate fiber diversity.
Iron and B12 must still be replaced—often parenterally at first—because the absorption machinery is damaged. Full iron panels, inflammatory markers, and redox indicators guide the process better than ferritin alone. The goal is not merely to normalize numbers but to restore the conditions under which those numbers remain normal without perpetual supplementation.
Practical Implications and Open Questions
The hypothesis predicts that interventions shown to improve mitochondrial function and gut-symbiont coherence—time-restricted feeding or medically supervised fasting where appropriate, dynamic resistance training, adequate animal-sourced protein and fat, fermented MACs, circadian light and sleep hygiene, and selective nutrient support for OXPHOS—should, over time, slow or partially reverse the progressive loss of parietal-cell mass and improve iron dynamics beyond what replacement alone achieves. Longitudinal data that include pre-diagnostic mitochondrial and microbiome metrics are still lacking; AIG is multifactorial and the relative weighting of genetic, infectious, and metabolic contributions will vary among individuals.
What is already clear is the limitation of a purely effector-focused model. Low ferritin that refuses to rise, progressive gastric atrophy despite "optimal" plant-based nutrition, and the co-occurrence of other autoimmune phenomena are not random misfortunes. They are coherent signals that the engine is under power. Restoring energetic coherence does not guarantee reversal of established AIG, but it addresses the upstream conditions that made the disease more likely and that continue to sustain it. That is the frugal path: work with the biology that evolution already engineered rather than indefinitely override its failures.
The goal remains understanding and restoring the engine.
It is offered as a working hypothesis, not clinical advice.
A working hypothesis, open to correction and revised as new evidence arrives. Last revised October 17, 2026.
Related: Sage — GI · Sage — Immune · Sage — Ferritin.
See the notice at the top of this page. Working hypothesis, not medical advice.